NCT02890355 2026-03-05FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting123 enrolled 15 charts